Cell and gene therapy services
Converge for Life Sciences
Our team of CGT industry innovators can help you optimize the coordination of your cell and gene therapy manufacturing ecosystem to enhance the end-to-end patient treatment journey.
Accelerate cell and gene therapy innovation
Providers, manufacturers, sponsors, and Contract Development and Manufacturing Organizations (CDMOs) face a multitude of challenges in the cell and gene therapy space. Disparate portals, time-intensive onboarding, high costs, and limited collaboration create a fractured experience in one of the fastest-growing industries within life sciences.
Our cell and gene therapy services put patients at the center of care with clear visibility into Chain or Identity (COI) and Chain of Custody (COC) across industry stakeholders, helping you optimize the coordination of your entire CGT ecosystem to drive IndustryAdvantage™ and enhance the patient treatment journey.
Benefits of our cell and gene therapy services
As a leader in the CGT industry, we have helped both small and large organizations transform their operations across the value chain. Backed by Converge for Life Sciences proprietary data, workflow, artificial intelligence (AI), and cloud software solutions, our people and technology work together to help you differentiate your business.
Life sciences solutions designed to accelerate your advantage
Our proprietary data, workflow, and AI solutions are built to help you address the problems of today with an eye on tomorrow, which can position your business to get ahead, and stay ahead, with more confidence.
Converge ecosystem and alliances
Our curated ecosystem of data and technology vendors aligns to the challenges we’re helping you address to reduce complexity and deliver outcomes that prepare you for the future. By incorporating new innovations from our ecosystem and continuously investing in our industry cloud platforms, our customizable solutions can help you achieve IndustryAdvantage™.
Christopher Zant
